Clinical Trial Detail

NCT ID NCT03727880
Title Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

pancreatic ductal adenocarcinoma

Therapies

Defactinib + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.